Cargando…

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Fixed-duration venetoclax plus rituximab (VenR) has a manageable safety profile and improves survival in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). We present data from the phase III MURANO study on the impact of venetoclax modification or premature discontinuation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mato, Anthony R., Sharman, Jeff P., Biondo, Juliana M.L., Wu, Mei, Mun, Yong, Kim, Su Y., Humphrey, Kathryn, Boyer, Michelle, Zhu, Qian, Seymour, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719076/ https://www.ncbi.nlm.nih.gov/pubmed/33327712 http://dx.doi.org/10.3324/haematol.2020.266486

Ejemplares similares

Murano
Publicado: (1969)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
por: Kater, Arnon P., et al.
Publicado: (2020)

Murano : Memoranda 73
Publicado: (1975)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
por: Ehsan, Hamid, et al.
Publicado: (2021)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
por: Niswander, Lisa M., et al.
Publicado: (2023)

Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
por: Barbier, Michaela, et al.
Publicado: (2021)

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
por: Davids, Matthew S., et al.
Publicado: (2021)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
por: Labrador, Jorge, et al.
Publicado: (2022)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
por: Piccini, Matteo, et al.
Publicado: (2023)

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
por: Gao, Xiaohui, et al.
Publicado: (2023)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
por: Lebel, Eyal, et al.
Publicado: (2023)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
por: Ceglédi, Andrea, et al.
Publicado: (2023)

Refractory Autoimmune Cytopenias Treated With Venetoclax
por: Gordon, Max J., et al.
Publicado: (2019)

P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS
por: Ghia, Paolo, et al.
Publicado: (2023)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
por: Liu, Kaiqi, et al.
Publicado: (2021)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r9jsovnsl1uhf31i24v8uej2ca